Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Giralt, Sergio  [Clear All Filters]
2014
Harris B, Morjaria S, Eric L, Giralt S, Stover D, Taur Y, Eric P. Pulmonary Complications Following Allogeneic-Hematopoietic Stem Cell Transplantation at a High-Volume, Academic Transplant Center. Chest. 2014;146(4_MeetingAbstracts):916A.
2015
Smith E, Devlin SM, Orlando E, Landau H, Lesokhin AM, Chung DJ, Hassoun H, Lendvai N, Landgren O, Giralt S, et al. CD34-selected allogeneic hematopoietic stem cell transplantation for patients with relapsed, high-risk multiple myeloma. Biol Blood Marrow Transplant. 2015.
Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L, Sengsayadeth S, Abidi M, Hari P, Mohty M, et al. Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the ASBMT. Biol Blood Marrow Transplant. 2015.
Feldman DR, Glezerman I, Patil S, Van Alstine L, Bajorin DF, Fischer P, Hughes A, Sheinfeld J, Bains M, Reich L, et al. Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors. Clin Genitourin Cancer. 2015.
Neofytos D, Huang Y-T, Cheng K, Cohen N, Perales M-A, Barker J, Giralt S, Jakubowski A, Papanicolaou G. Safety and Efficacy of Intermittent Intravenous Administration of High-Dose Micafungin. Clin Infect Dis. 2015;61(suppl 6):S652-S661.
2018
Liu Y, Han H, Shah G, Giralt S, C Landgren O, He J, Lesokhin AM. Significant Nationwide Variability exists in the Costs and in Hospital Mortality Rates in Autologous Stem Cell Transplant for Multiple Myeloma: An Analysis of the Nationwide Inpatient Sample (NIS) Database. Biol Blood Marrow Transplant. 2018.
2019
Tamari R, Rapaport F, Zhang N, McNamara C, Kuykendall A, Sallman DA, Komrokji R, Arruda A, Najfeld V, Sandy L, et al. Impact of high molecular risk mutations on transplant outcomes in patients with myelofibrosis. Biol Blood Marrow Transplant. 2019.
Landau H, Lahoud O, Devlin S, Lendvai N, Chung DJ, Dogan A, C Landgren O, Giralt S, Hassoun H. Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis. Biol Blood Marrow Transplant. 2019.
Deng G, Giralt S, Chung DJ, Landau H, Siman J, Li QS, Lapen K, Mao JJ. Reduction of Opioid Use by Acupuncture in Patients Undergoing Hematopoietic Stem Cell Transplantation: Secondary Analysis of a Randomized, Sham-Controlled Trial. Pain Med. 2019.
Giralt S, Costa LJ, Maloney D, Krishnan A, Fei M, Antin JH, Brunstein C, Geller N, Goodman S, Hari P, et al. Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma: Long-term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial. Biol Blood Marrow Transplant. 2019.
2020
Pennisi M, Jain T, Santomasso BD, Mead E, Wudhikarn K, Silverberg MLynne, Batlevi Y, Shouval R, Devlin SM, Batlevi C, et al. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Adv. 2020;4(4):676-686.
Fang J, Su Y, Zavras PD, Raval AD, Tang Y, Perales M-A, Giralt S, Stern A, Papanicolaou GA. Impact of preemptive therapy for Cytomegalovirus on hospitalizations and cost after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020.
Bejanyan N, Zhang M, Bo-Subait K, Brunstein C, Wang H, Warlick ED, Giralt S, Nishihori T, Martino R, Passweg J, et al. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate, but not High Disease Risk Index: A CIBMTR Study: Superior DFS with MAC comp. Biol Blood Marrow Transplant. 2020.
Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Popat U, Alousi AM, Hosing C, Giralt S, Rondon G, et al. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv. 2020;4(21):5580-5588.
2021
Shouval R, Fein JA, Labopin M, Cho C, Bazarbachi A, Baron F, Bug G, Ciceri F, Corbacioglu S, Galimard J-E, et al. Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. Lancet Haematol. 2021;8(3):e205-e215.
Rodriguez N, Lee J, Flynn L, Murray F, Devlin SM, Soto C, Cho C, Dahi P, Giralt S, Perales M-A, et al. Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell Transplantation. Transplant Cell Ther. 2021.
Sidana S, Kumar S, Fraser R, Estrada-Merly N, Giralt S, Agrawal V, Anderson LD, Aljurf M, Banerjee R, Bashey A, et al. Title: Impact of Induction Therapy with VRD vs. VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. Transplant Cell Ther. 2021.
Feinstein MB, Habtes I, Giralt S, Stover DE. Utility of Bronchoscopy with Bronchoalveolar Lavage among Hematologic Transplant Recipients in the Era of Noninvasive Testing. Respiration. 2021:1-8.
2023
Iskandarani SEl, Sun L, Li SQing, Pereira G, Giralt S, Deng G. Acupuncture improves certain aspects of sleep in hematopoietic stem cell transplantation patients: a secondary analysis of a randomized controlled trial. Acupunct Med. 2023:9645284231181403.
Nagesh PKB, Monette S, Shamu T, Giralt S, St Jean SC, Zhang Z, Fuks Z, Kolesnick R. Anti-ceramide Single-Chain Variable Fragment Mitigates Gastrointestinal-Acute Radiation Syndrome and Improves Marrow Reconstitution, Rendering Near-Normal 90-Day Autopsies. Int J Radiat Oncol Biol Phys. 2023.
Ptashkin RN, Ewalt MD, Jayakumaran G, Kiecka I, Bowman AS, Yao JJ, Casanova J, Lin Y-TDavid, Petrova-Drus K, Mohanty AS, et al. Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing. Nat Commun. 2023;14(1):6895.
Nath K, Peterson K, Brown S, Devlin S, Rodriguez N, Barker J, Giralt S, Gyurkocza B, Jakubowski A, Papadopoulos E, et al. Reduced Intensity Compared to Non-myeloablative Conditioning in Patients with Non-Hodgkin Lymphoma undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2023.
Prockop SE, Hasan AN, Doubrovina E, Dahi PB, M Rodriguez-Sanchez I, Curry M, Mauguen A, Papanicolaou GA, Su Y, Yao JJ, et al. Third party CMV viral specific T-cells for refractory CMV viremia and disease after hematopoietic transplant. J Clin Invest. 2023.
2024
Krystel-Whittemore M, Petrova-Drus K, Ptashkin RN, Ewalt MD, Yao JJ, Liu Y, Zhu M, Benhamida J, Durham B, Kumar J, et al. Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignancies. Haematologica. 2024.
Malek E, Kort J, Metheny L, Fu P, Li G, Hari P, Efebera Y, Callander NS, Qazilbash MH, Giralt S, et al. Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial. Transplant Cell Ther. 2024.